Preferences help
enabled [disable] Abstract
Number of results
2011 | 6 | 5 | 575-581
Article title

Continuous subcutaneous insulin infusion vs. multiple daily injections

Physical description
1 - 10 - 2011
9 - 8 - 2011
  • Clinic for Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center Niš, Bulevar Dr Zorana Djindjica 48, 18000, Niš, Serbia
  • [1] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986[Crossref]
  • [2] UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998;352:837–853[Crossref]
  • [3] Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001;358:739–746[Crossref]
  • [4] Pickup J, Keen H. Continuous subcutaneous insulin infusion 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25:593–598[Crossref]
  • [5] Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705–708[Crossref]
  • [6] Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L: Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23:583–588[Crossref]
  • [7] Zinman B: Insulin pump therapy and rapid acting insulin: what have we learned? Int J Clin Pract 2001;123:47–50
  • [8] Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 2006;23:285–292[Crossref]
  • [9] Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004;21:1213–1220[Crossref]
  • [10] Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, et al. Comparison of a multiple daily insulin injection regimen (basal oncedaily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009;32:1170–1176[Crossref][WoS]
  • [11] Harmel AP, Mathur R. Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. Diabetes Care 2004;27:272–273[Crossref]
  • [12] Davidson P, Hebblewhite H, Steed R, Bode B. A deductive framework to aid in understanding CSII parameters: carbohydrate-to-insulin ratio (CIR) and correction factor (CF). Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association; June 13–17, 2003; New Orleans, Louisiana. Abstract 443-P
  • [13] Hannaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber J. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. Diabetes Care 2000;23:1232–1235[Crossref]
  • [14] Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004;27:1554–1558[Crossref]
  • [15] Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31Suppl 2:S140–S145[Crossref]
  • [16] Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabetic Medicine 2008;25:765–774[Crossref]
  • [17] Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: The impact of baseline A1c. Diabetes Care 2004:27:2590–2596[Crossref]
  • [18] Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006;117:2126–2131[Crossref]
  • [19] Fahlén M, Eliasson B, Oden A. Optimization of basal insulin delivery in type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Diabetic Medicine 2005;22:382–386[Crossref]
  • [20] Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26:1079–1087[Crossref]
  • [21] Karagianni P, Sampanis Ch, Katsoulis Ch, Miserlis G, Polyzos S, Zografou I, et al. Continuous subcutaneous insulin infusion versus multiple daily injections. Hippokratia 2009;13:93–96
  • [22] Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, et al. Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Regimens in Children with Type 1 Diabetes: A Randomized Open Crossover Trial. Pediatrics 2003;112:559–564[Crossref]
  • [23] The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711–1721[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.